Top Railroad Companies To Own For 2014

Worried about future inflation? Ben Shepherd's new advisory, Inflation Survival Letter, is designed to protect portfolios against the risks of inflation; he highlights one favorite inflation-resistant stock, a leading railroad operator.

Steve Halpern: We're here today with Ben Shepherd, editor of the Inflation Survival Letter. How are you doing today, Ben?

Ben Shepherd: Terrific, Steve, how are you?

Steve Halpern: Good. Could you tell our listeners a little about your newsletter and an overview of your investing strategy?

Ben Shepherd: Sure. I've been concerned about the prospect of inflation, really ever since the US Federal Reserve implemented its zero interest rate policy and began aggressively pursuing a program of quantitative easing.

I believe one of government's greatest functions is to, kind of, smooth out the economic bumps in the road, but unfortunately, it has an extremely poor track record of timing its actions to do the most good, while doing the least harm.

Top Railroad Companies To Own For 2014: Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd. is an Israel-based biopharmaceutical company. The Company is focused on the development and acquisition of therapeutic candidates. The Company�� pipeline consists of six late clinical development therapeutic candidates, two of which have completed bioequivalence clinical trials subject to review and approval by the United States Food and Drug Administration and, in some cases, regulatory authorities in other countries. The Company�� six clinical stage therapeutic candidates include RHB-101, RHB-102, RHB-103, RHB-104, RHB-105 and RHB-106.

RHB-101

RHB-101 is a treatment of hypertension, heart failure and left ventricular dysfunction (following myocardial infraction) by means of controlled release of an active ingredient known as carvedilol, which is designed to be administered to patients on a once-daily basis. RHB-101 is based on a patented technology for the controlled release of drugs administered orally.

RHB-102

RHB-102 is a once-daily controlled release oral formulation of ondansetron. RHB-102 utilizes a technology called CDT that uses salts to provide a controlled release of ondansetron.

RHB-103

RHB-103 is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. Migraine is a neurovascular disorder (related to nerves and blood vessels) characterized by recurrent headaches in one side or both sides of the head.

The product is based on a technology called VersaFilm.

RHB-104

RHB-104 is an antibiotic combination therapy for the treatment of Crohn's disease (with a PIII clinical study underway), as well as Multiple Sclerosis (with an ongoing PIIa clinical study) and Rheumatoid Arthritis. RHB-104 is a combination of clarithromycin, clofazimine and rifabutin, three generic antibiotic ingredients, in a single capsule.

RHB-105

RHB-105, an antibiotics and proton pump inhibitor drug targeting Helico! bacter Pylori infection. RHB-105 is a combination of three approved drug products omeprazole, which is a proton pump inhibitor (the natural body pump that produces the gastric acids used for digesting the food in the stomach), and amoxicillin and rifabutin which are antibiotics. Chronic infection with Helicobacter pylori irritates the mucosal lining of the stomach and small intestine.

RHB-106

RHB-106, is a tablet for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. Its abdominal procedures include diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.

The company competes with GlaxoSmithKline, Sanofi-Aventis Groupe, Hoffman-La Roche Ltd, Merck and Co., Inc, Ferring Pharmaceuticals and Salix Pharmaceuticals Inc.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Vitran Corporation (NASDAQ: VTNC) announced today that it has entered into a definitive arrangement agreement with TransForce pursuant to which TransForce has agreed to acquire all of the outstanding common shares of Vitran not already owned by TransForce for US$6.50 in cash per share, in accordance with TransForce's prior proposal. To read the full news, click here. ReneSola (NYSE: SOL) today announced it signed a Memorandum of Intent (MOI) to sell three utility-scale projects in Western China, with a total capacity of 60MW, to Jiangsu Akcome Solar Science & Technology Co on December 30, 2013. To read the full news, click here. Cooper Tire & Rubber Company (NYSE: CTB) today announced it has terminated the merger agreement with Apollo Tyres (NSE:ApolloTYRE). To read the full news, click here. RedHill Biopharma (NASDAQ: RDHL) today announced that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, for the sale of RedHill's American Depository Shares and warrants in a private placement transactionor a total sum of $6.0 million. To read the full news, click here.

  Posted-In: Guggenheim US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Top Railroad Companies To Own For 2014: Niska Gas Storage Partners LLC (NKA)

Niska Gas Storage Partners LLC owns and operates natural gas storage assets in North America. It owns or contracts for approximately 185.5 billion cubic feet of total gas storage capacity. The company owns and operates gas storage facilities in Alberta, Canada, as well as in northern California and Oklahoma, the United States. Its gas storage customers include financial institutions, producers, marketers, power generators, pipelines, and municipalities. The company was founded in 2006 and is headquartered in Houston, Texas.

Advisors' Opinion:

• [By Seth Jayson]

  Niska Gas Storage Partners (NYSE: NKA  ) is expected to report Q1 earnings on Aug. 1. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Niska Gas Storage Partners's revenues will contract -1908.0% and EPS will contract -9.5%.

• [By Emma O��rien]

  S&P 500 futures lost 0.8 percent by 7:22 a.m. in Tokyo, after the measure slid 1.1 percent last week in its first decline this month. Contracts on Australia�� S&P/ASX 200 Index dropped 0.2 percent and Nikkei 225 Stock Average (NKA) futures lost 0.5 percent by 3 a.m. in Osaka. The greenback retreated 0.3 percent to 97.91 yen, while U.S. Treasury futures climbed. West Texas Intermediate oil and copper futures sank 0.8 percent.

• [By Seth Jayson]

  Niska Gas Storage Partners (NYSE: NKA  ) reported earnings on May 9. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q4), Niska Gas Storage Partners whiffed on revenues and crushed expectations on earnings per share.

Best Value Companies To Buy For 2014: Consumer Portfolio Services Inc.(CPSS)

Consumer Portfolio Services, Inc. operates as a specialty finance company in the United States. It engages in purchasing and serving retail automobile contracts originated by franchised automobile dealers and select independent dealers in the sale of new and used automobiles, light trucks, and passenger vans. The company, through its automobile contract purchases, provides indirect financing to dealer customers for borrowers with limited credit histories, low incomes, or past credit problems. It serves as an alternative source of financing for dealers, allowing sales to customers who might not be able to obtain financing. The company also directly finances consumers for vehicle purchases. Consumer Portfolio Services, Inc. provides its automobile contracts through its headquarters and three servicing branches in Virginia, Florida, and Illinois. The company was founded in 1991 and is headquartered in Irvine, California.

Advisors' Opinion:

• [By Rick Munarriz]

  Finally, we have Consumer Portfolio Services (NASDAQ: CPSS  ) driving past where the pros were parked. Consumer Portfolio Services provides indirect automobile financing, primarily to folks with dodgy credit histories buying late-model used cars. This is a risky niche when the economy's souring, but business is booming these days.

Top Railroad Companies To Own For 2014: Morgan Stanley(MS)

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. It operates in three segments: Institutional Securities, Global Wealth Management Group, and Asset Management. The Institutional Securities segment offers financial advisory services on mergers and acquisitions, divestitures, joint ventures, corporate restructurings, recapitalizations, spin-offs, exchange offers, and leveraged buyouts and takeover defenses, as well as shareholder relations, capital raising, corporate lending, and investments. This segment also engages in sales, trading, financing, and market-making activities, including equity trading, commodities, and interest rates, credit, and currencies, as well as financing services, such as prime brokerage, consolidated clearance, settlement, custody, financing, and portfolio reporting services. The Global Wealth Management Group segment provide s brokerage and investment advisory services covering various investment alternatives comprising equities, options, futures, foreign currencies, precious metals, fixed income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs; education savings programs, financial and wealth planning services, and annuity and insurance products; credit and other lending products; cash management services; retirement services; and trust and fiduciary services. The Asset Management segment offers products and services in equity, fixed income, and alternative investments, such as hedge funds, fund of funds, real estate, private equity, and infrastructure to institutional and retail clients through proprietary and third party distribution channels. This segment also involves in investment and merchant banking activities. The company was founded in 1935 and is headq uartered in New York.

Advisors' Opinion:

• [By U.S. News]

  Getty Images The financial media loves a crisis, and we have no shortage of them. The government shutdown and the looming possibility of a default provide ample fodder for those whose livelihoods depend on readers, viewers and advertising revenue. The major advertisers in financial media are members of the securities industry. This industry depends on trading by investors to increase fees and commissions. It's the perfect storm for investors. Much of the media acts as a shill for its advertisers by increasing fear and anxiety, which, in turn, stimulates trading as investors flee to safety and wait on the sidelines until things settle down. Bouncing in and out of the market in response to market volatility is a recipe for poor returns. A University of Michigan study commissioned by Towneley Capital Management found that investors who missed less than 1 percent of the best trading days from 1963 through 2004 did not capture 96 percent of market returns. Another analysis of market-timing strategies over a 10-year period found that 80 percent of market timers failed over any reasonable period of time. Those are not encouraging odds. Terrible advice abounds in these times. Jim Cramer, a common source of hype and misinformation, warns that all stocks will "get clocked" as the prospect of default nears. He suggests buying dividend-paying stocks as "bounce back candidates." Cramer doesn't reference the extensive data indicating that using high-dividend stocks as a substitute for safe bonds is risky and a poor substitute for an intelligently implemented value strategy. A blog post from CNBC reports a prediction from investment bank Societe Generale that U.S. shares are "headed for a big drop in the first quarter of 2014, followed by a year-long period of stagnation." Another post from CNBC warns that a "debt freeze would throw the economy hard into reverse and another deep recession." You don't need to look far to understand how the securities industry benefits

• [By Chad Fraser]

  The financial gains all come down to two companies, according to FactSet: Bank of America and Morgan Stanley (NYSE: MS), which are up against weak comparisons from a year ago. Set those two aside, and you’re looking at a 0.6% earnings contraction for the sector.

• [By Paul Ausick]

  Shares of Twitter Inc. (NYSE: TWTR) tumbled 4% Monday following a downgrade to Underweight by Morgan Stanley (NYSE: MS). The stock continues its slide today, dropping another 6.5% with no other news driving the price.

• [By Matt Koppenheffer and David Hanson]

  Morgan Stanley (NYSE: MS  ) lead the way, but solid gains continued for Bank of America (NYSE: BAC  ) and some others. In this video, Motley Fool banking analysts Matt Koppenheffer and David Hanson discuss these banks and what the environment looks like going forward.

Top Railroad Companies To Own For 2014: Red Lion Hotels Corporation(RLH)

Red Lion Hotels Corporation, a hospitality and leisure company, engages in the ownership, operation, and franchising of midscale, full, select, and limited service hotels under the Red Lion brand. As of June 30, 2011, its hotel network comprised of 44 hotels located in 8 states and 1 Canadian province, with 8,457 rooms. The company also offers ticketing services and promotion and presentation of entertainment productions, as well as provides ticketing inventory management systems, call center services, and outlet/electronic channel distribution for event locations. In addition, it has direct ownership interest in a retail mall in Kalispell, Montana, as well as involves in the real estate investments. The company was formerly known as WestCoast Hospitality Corporation and changed its name to Red Lion Hotels Corporation in September 2005. Red Lion Hotels Corporation was founded in 1937 and is based in Spokane, Washington.

Advisors' Opinion:

• [By Laura Brodbeck]

  Monday

  Earnings Releases Expected: Sotheby�� (NYSE: BID), Otelco (NASDAQ: OTEL), Rackspace Hosting, Inc. (NYSE: RAX), Red Lion Hotels Corporation (NYSE: RLH) Economic Releases Expected: Italian industrial production, Mexican industrial production, Portuguese trade balance

  Tuesday

Top Railroad Companies To Own For 2014: Epizyme Inc (EPZM)

Epizyme, Inc., incorporated on November 1, 2007, is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. The Company systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of its product candidates is directed towards patients with a particular genetically defined cancer.The Company is conducting a Phase I clinical trial of its advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage leukemia (MLL-r). The Company has identified its two lead product candidates using its product platform.

EPZ-5676-DOT1L Inhibitor

EPZ-5676 is an intravenously administered small molecule inhibitor of DOT1L. The Company is developing EPZ-5676 for the treatment of MLL-r, an aggressive subtype of the two most common forms of acute leukemia, ALL and AML. Patients with MLL-r are routinely diagnosed with existing technologies that are commonly used in clinical setting. The Company�� Phase 1 clinical trial of EPZ-5676 is an open label, multicenter trial that has two phases.

EPZ-6438-EZH2 Inhibitor

The Company is developing EPZ-6438 as an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients who have an oncogenic point mutation in EZH2. EZH2 is an HMT that can become oncogenic and cause non-Hodgkin lymphoma and a range of other solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are particularly associated with an EZH2 point mutation. There are no therapies approved specifically for the treatment of cancer associated with an EZH2 point mutation.

Advisors' Opinion:

• [By John Udovich]

  On Tuesday, small cap biopharmaceutical company Epizyme Inc (NASDAQ: EPZM) surged 75.56% after the company announced that its�EPZ-5676, a DOT1L inhibitor for acute leukemias, had reached its proof-of-concept milestone, meaning its worth taking a closer look at the stock as well as look at the share performance of cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Dendreon Corporation (NASDAQ: DNDN) and Geron Corporation (NASDAQ: GERN).

• [By Dan Caplinger]

  Outside the Dow, there were a few winners. Guess? (NYSE: GES  ) climbed 8% after a better-than-expected earnings performance, despite the fact that profits fell from year-ago levels. The retailer repeated what we've heard from its peers about bad weather conditions having a negative impact on the company, and its European operations also struggled. Meanwhile, biotech IPO Epizyme (NASDAQ: EPZM  ) soared more than 50% after coming public at $15 this morning. The company has a promising technology in treating cancer caused by carcinogenic genes, and it has collaborations with several major drug companies that should help it push some of its potential treatments through the pipeline.

• [By Laura Brodbeck]

  Friday

  Earnings Expected From: Epizyme (NASDAQ: EPZM), Dyax Corp (NASDAQ: DYAX) Economic Releases Expected: ��German GDP, German business climate index, Italian retail sales.

  Get all the #premarket info by listening in to Benzinga's morning show at 8:00 am EST Monday-Friday!

Top Railroad Companies To Own For 2014: Ceres Inc (CERE)

Ceres, Inc. (Ceres), incorporated in March 1996, is an agricultural biotechnology company selling seeds to produce renewable biomass feedstocks that can enable the large-scale replacement of petroleum and other fossil fuels. The Company�� large-scale commercial products are sweet sorghum varieties that can be used as a drop-in feedstock to extend the operating season of Brazilian sugarcane-to-ethanol mills. Its products include sweet sorghum, high biomass sorghum, switchgrass, miscanthus and row crops. Its energy crops can also be used for the production of second-generation biofuels and bio-based chemicals, including cellulosic ethanol, butanol, jet fuel, diesel-like molecules and gasoline-like molecules, from non-food biomass. Baseload utility scale electric power can also be generated from the biomass feedstocks grown from its seeds. Ceres has started marketing sweet sorghum seeds in Brazil and has sold switchgrass and high biomass sorghum seeds in the United States under its brand, Blade Energy Crops (Blade). In January 2010, the Company incorporated a subsidiary, Ceres Sementes do Brasil Ltda.

The Company generates its revenues from government grants, research and development collaboration agreements and from product sales. Product sales primarily consists of sales of seeds. Collaborative research revenues consist of payments for research and development activities for specific projects. Government grant revenues consist of payments from government entities. Ceres markets its seeds and traits directly to ethanol mills, utilities, independent power producers, cellulosic biofuel companies, individual growers and grower cooperatives. It also works with technology providers and other market participants, such as equipment manufacturers and enzyme or fermentation technology companies. The Company markets its products to biorefineries and biopower facilities.

Ceres�� activities in cellulosic biofuels encompass a range of activities, including field trials, co-evolution agr! eements, and commercial sales. Its products have been tested in the conversion processes of EdeniQ, Inc., Choren USA LLC, Gruppo M&G, ICM, Inc., and UOP, LLC (a Honeywell company), among others. The Company has also conducted joint trials with, or sold seed to, AGCO Corporation, EdeniQ, Inc. and Hawai�� BioEnergy, LLC, among others. It has begun collaboration with Valero Services, Inc. to further evaluate feedstock supply strategies with energy crops. Ceres also works with refining technology companies to optimize feedstock for their refining processes. These collaborators include Novozymes North America, Inc. and ThermoChem Recovery International, Inc.

Drop-in Products

The Company�� products are drop-in solutions as they can be planted, harvested and processed using existing agricultural equipment with little or no modification and are being developed to be drop-in for all conversion technologies using sugarcane or biomass feedstocks, facilitating their rapid adoption. In collaboration with Boa Vista/Nova Fronteira, which is a joint venture of ethanol producers Grupo Sao Martinho, S.A. and Petrobras Biofuels, the Company has completed a commercial-scale trial on approximately 250 hectares of its sweet sorghum, which was planted and harvested using existing planting and harvesting equipment, fermented into ethanol without retrofitting or altering the existing mill and the remaining biomass combusted for electricity production, using existing boilers. It has also conducted smaller trials using its other energy crops with numerous industry participants engaged in cellulosic biofuels and biopower production. The Company�� products have been tested in the conversion processes of Amyris Biotechnologies, Inc., Choren USA LLC, EdeniQ, Inc., Gruppo M&G, ICM, Inc., Novozymes North America, Inc., ThermoChem Recovery International, Inc. and UOP, LLC (a Honeywell company), among others. DuPont Danisco Cellulosic Ethanol LLC (DDCE) also plans to validate the Company�� products in th! eir conve! rsion process.

Sweet Sorghum

Sweet sorghum is a type of sorghum that accumulates free sugars in its stalk. It is sown by seed, and requires less water and nitrogen fertilizer to grow to harvestable maturity. Sweet sorghum plants can be harvested in 90 to 140 days after sowing. Because sweet sorghum is an annual crop, multiple harvests or crop rotations may be possible during the season.

High Biomass Sorghum

High biomass sorghum is a type of sorghum, which is primarily developed for biomass yield. As such, high biomass sorghum is suited for the generation of renewable electric power and the creation of cellulosic biofuels. High biomass types are seed propagated, and requires less water and nitrogen fertilizer. As an annual crop, sorghum is harvested the year it is planted. This provides bioenergy facilities with a growing and flexible source of biomass, and a complementary feedstock to perennials, such as sugarcane or switchgrass. The Company�� ES 5200 and ES 5201 products contains its Skyscraper trait. These hybrids, developed through its partnership with Texas A&M University, are designed for single-cut production systems.

Switchgrass

Switchgrass is a perennial grass indigenous to North America that offers high biomass yield potential. It requires less water and nitrogen fertilizer, and can grow under semi-arid conditions. Switchgrass is seed propagated. As a perennial, switchgrass is not harvested for sale during the first year when the crop is being established. A properly managed stand of switchgrass may persist for a decade. During the year ended December 31, 2010, it introduced three products: EG 1101, EG 1102 and EG 2101. These high-yielding varieties is developed through its partnership with The Samuel Roberts Noble Foundation.

Miscanthus

Miscanthus x giganteus is a tall perennial grass that grows well in cooler climates. It is vegetatively propagated. It has been used as an energy crop on ! a small s! cale across Europe. The Miscanthus genus includes several perennial species that has energy crops. The variety adopted in the United States and Europe, miscanthus x giganteus, is a sterile hybrid of M. sinensis and M. sacchariflorus. This miscanthus hybrid requires about the same water as corn, but up to two-thirds less nitrogen depending on crop management practices. As a perennial crop, miscanthus is not harvested for sale during the first year when the crop is being established. Ceres is also working on extending the region of adaptation. To these ends, the Company is collaborating with the Institute of Biological, Environmental, and Rural Sciences of Aberystwyth University in Wales, the United Kingdom.

The Company competes with Advanta India Limited, The Dow Chemical Company, Monsanto Company, Pioneer Hi-Bred (DuPont), KWS and Syngenta.

Advisors' Opinion:

• [By Roberto Pedone]

  Another renewable energy player that looks ready to trigger a big breakout trade is Ceres (CERE), which sells seeds to produce renewable biomass feedstocks that can enable the large-scale replacement of petroleum and other fossil fuels. This stock has been hammered by the bears so far in 2013, with shares off sharply by 66%.

  If you take a look at the chart for Ceres, you'll notice that this stock has just started to trend back above its 50-day moving average of $1.45 a share with heavy upside volume flows. Volume so far today has already registered over 1.15 million shares, which is well above its three-month average action of 670,538 shares. This spike back above its 50-day is now quickly pushing shares of CERE within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in CERE if it manages to break out above some near-term overhead resistance levels at $1.67 to $1.68 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 670,538 shares. If that breakout hits soon, then CERE will set up to re-test or possibly take out its next major overhead resistance levels at $2 to $2.50 a share. Shares of CERE could even tag $3 if this breakout triggers with strong volume.

  Traders can look to buy CERE off any weakness to anticipate that breakout and simply use a stop that sits right below $1.40 a share. One could also buy CERE off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Maxx Chatsko]

  Shares of energy crop developer Ceres (NASDAQ: CERE  ) surged more than 100% from the opening bell Monday to early trading on Thursday. In fact, over one-third of the total outstanding shares traded hands on Thursday. Even with the move the company is trading for "only" $100 million. With some of the biggest names in industrial biotech on its side -- such as Syngenta (NYSE: SYT  ) , Petrobras, Amyris, Valero, Novozymes, Gruppo M&G, and Mascoma, to name a few -- this must be a good buy right? Not so fast.

• [By James E. Brumley]

  Despite the fact that markets are right around breakeven levels for Wednesday, there are relatively few stocks that are up today, and even fewer that are up on strong volume. For the NYSE, 54% of its listed equities are in the red this morning, and 58% of the total volume seen so far has been bearish volume. That's what makes Ceres Inc. (NASDAQ:CERE) so interesting early Wednesday. As one of the few tickers that's not only up, but up on higher volume, CERE is a standout worth a closer look. And, that closer look reveals something even more compelling about the way things are coming together for this small cap stock.